TiumBio Co. Ltd
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The co… Read more
TiumBio Co. Ltd (321550) - Total Assets
Latest total assets as of September 2025: ₩103.44 Billion KRW
Based on the latest financial reports, TiumBio Co. Ltd (321550) holds total assets worth ₩103.44 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
TiumBio Co. Ltd - Total Assets Trend (2017–2024)
This chart illustrates how TiumBio Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
TiumBio Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
TiumBio Co. Ltd's total assets of ₩103.44 Billion consist of 54.9% current assets and 45.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩16.44 Billion | 0.0% |
| Accounts Receivable | ₩1.76 Billion | 1.6% |
| Inventory | ₩356.06 Million | 0.3% |
| Property, Plant & Equipment | ₩44.72 Billion | 41.7% |
| Intangible Assets | ₩423.44 Million | 0.4% |
| Goodwill | ₩1.33 Billion | 1.2% |
Asset Composition Trend (2017–2024)
This chart illustrates how TiumBio Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TiumBio Co. Ltd's current assets represent 54.9% of total assets in 2024, a decrease from 64.7% in 2017.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 22.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 26.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 41.7% of total assets.
TiumBio Co. Ltd Competitors by Total Assets
Key competitors of TiumBio Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
TiumBio Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - TiumBio Co. Ltd generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - TiumBio Co. Ltd is currently not profitable relative to its asset base.
TiumBio Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.18 | 39.32 |
| Quick Ratio | 1.34 | 1.18 | 39.32 |
| Cash Ratio | 0.00 | 0.19 | 0.00 |
| Working Capital | ₩14.42 Billion | ₩ 4.08 Billion | ₩ 68.07 Billion |
TiumBio Co. Ltd - Advanced Valuation Insights
This section examines the relationship between TiumBio Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.40 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -10.2% |
| Total Assets | ₩107.30 Billion |
| Market Capitalization | $93.90 Million USD |
Valuation Analysis
Below Book Valuation: The market values TiumBio Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: TiumBio Co. Ltd's assets decreased by 10.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for TiumBio Co. Ltd (2017–2024)
The table below shows the annual total assets of TiumBio Co. Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩107.30 Billion | -10.25% |
| 2023-12-31 | ₩119.55 Billion | +24.19% |
| 2022-12-31 | ₩96.26 Billion | -17.54% |
| 2021-12-31 | ₩116.73 Billion | +36.77% |
| 2020-12-31 | ₩85.35 Billion | -8.67% |
| 2019-12-31 | ₩93.46 Billion | +218.71% |
| 2018-12-31 | ₩29.32 Billion | +189.71% |
| 2017-12-31 | ₩10.12 Billion | -- |